Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Study Identifier
210669-010
CT.gov Identifier
NCT01001195
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • AGN-210669 ophthalmic solution, 0.1%
  • AGN-210669 ophthalmic solution, 0.075%
  • AGN-210669 ophthalmic solution, 0.05%
  • bimatoprost ophthalmic solution 0.03%
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Ocular hypertension or primary open-angle glaucoma in each eye * Patient requires IOP lowering medication in each eye
    Exclusion Criteria:
    * Ocular hyperemia or other ocular surface findings in either eye * Active ocular disease * Current or anticipated use of any topical ocular medication (including artificial tears) during the study * Intraocular surgery within past six months or unilateral cataract surgery. * Functionally significant visual field loss * Anticipated wearing of contact lenses during study * Use of other medications that affect IOP such as glaucoma treating medications, within 2 months of screening visit

    Protocol Summary

    This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

    Study Locations

    Location
    Status
    Location
    Rochester, New York, United States
    Status
    Not applicable